ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 1, 2008, Pages 55-63

  Ertault Daneshpouy, Marjan ^a   Noguera, Maria Elena ^a   Gisselbrecht, Christian ^a   Haddad, Albert ^a   Brice, Pauline ^a   Marolleau, Jean Pierre ^a   Soulier, Jean ^a   Mounier, Nicolas ^a,b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

CD38; Chronic lymphocytic leukemia; Flow cytometry; ZAP 70

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; PROTEIN KINASE ZAP 70; BIOLOGICAL MARKER; CD38 PROTEIN, HUMAN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY LABELING; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; B LYMPHOCYTE; BLOOD; CLASSIFICATION; METABOLISM; MIDDLE AGED;

ANTIGENS, CD38; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 41449092567     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fais F. Ghiotto F. Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
2. Maloum, K, Pritsch O, Magnac C, et al. VH gene expression int CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Leuk lymphoma. 1997;24:437-448.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated lg V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
4. Krober A, Seller T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
5. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
6. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005;105:3042-3050.
7. Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphoytic leukaemia. Leukemia. 2002; 16:30-35.
8. lbrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181-186.
9. Hamblin TJ, Orchard JA, Ibbotson RE, et al, CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood, 2002;99:1023-1029.
10. Rosenwald A. Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194:16-39-1647.
11. Chen L, Widhopf G, Húynh L, et al. Expression of ZAP-70 is associated with increased B-cell) receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609-4614.
12. Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science. 1994;264:1596-1599.
13. Iwashima M, Irving BA, van Oers NS, Chain AC, Weiss A. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine, kinases. Science. 1994;263:1136-1139.
14. Crespo M, Bosch F, Villamor N. et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
15. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
16. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363;105-111
17. Bakke AC, Puttzer Z, Leis J, Huang J. A robust ratio metric method for analysis of Zap-70 expression in chronic. lymphocytic leukemia (CLL.). Cytometry B Clin Cytom. 2006;70:227-234.
18. Del Principe MI, Del Poeta G, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006; 108:853-861.
19. Tinhofer I, Rubenzer G. Holler C, Hofstaetter E. Stoecher M, Egle A, Steurer M, Greil R. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood. 2006; 108:2950-2956.
20. Marutes E, Owusu-Ankomah K. Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8;1640-1645.
21. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis arid treatment. Blood. 1996;87:4990-4997.
23. Kaplan EL, Meier P. Nort parametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-481.
24. Cox D. Regression model and life tables. J R Statist Soc B. 1972;34:187-220.
25. Del Poeta G, Maurillo L., Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98:2633-2639.
26. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
27. Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol, 2005;27:258-266.
28. Passam F, Tachynopoulou V, Skoumi D, et al. Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: a methodological approach. Ann Hematol. 2006;85: 795-805.
29. Bojarska-Junak A, Rolinski J, Kawiak J. Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia. Folia Histochem Cytobiol. 2005;43:19-23.
30. Herishanu Y, Kay S, Rogowski O, et al. T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression. Leukemia. 2005;19:1289-1291
31. Folarin NI, Baker RJ, Duke V, et al. Detection of ZAP-70 by flow cytometry using the highly fluorescent alexa fluor dye in cells from patients with chronic lymphocytic leukaemia (CLL). The Hematology Journal. 2004;5:S23.
32. Schroers R, Griesinger F, Trumper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression ill B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:750-758.
33. Dürig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17:2426-2434.
34. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
35. Del Giudice I, Morilla A, Osuji N, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2005;104:2124-2132.